Spero Therapeutics shares are trading lower. The company announced an exclusive license agreement with Innovent Biologics for SP001, a third‑gen Fc‑silent anti‑CD40L antibody.

Benzinga Newsdesk www.benzinga.com Positive 61.5%

Neg 0% Neu 0% Pos 61.5%

Comments

No comments yet. Be the first!